A naked mole rat can outlive a typical lab mouse by a factor of ten, surviving more than four decades while almost never developing cancer. The figure of 41 years is widely cited, though some sources place the confirmed maximum in captivity closer to 37 years; the precise upper bound remains approximate. For years, biologists Vera Gorbunova and Andrei Seluanov at the University of Rochester have been trying to figure out why. Their answer centers on a single molecule: an unusually large form of hyaluronan, a sugar-based polymer that cushions joints, fills the spaces between cells, and helps tissues hold their shape. In a study published in Nature, the team reported that transferring the naked mole rat gene responsible for producing this molecule into ordinary mice made them live longer, develop fewer tumors, and show signs of healthier aging across multiple organs.
“We expected to see some cancer protection, but we were pleasantly surprised to see an increase in lifespan as well,” Gorbunova told reporters when the study was published. The result has drawn sustained attention in aging research circles, and as of June 2026, it remains one of the most concrete demonstrations that a longevity trait from one species can be functionally transferred to another.
A molecule that acts like biological armor
Hyaluronan is not exotic. Human bodies produce it constantly. It lubricates joints, supports wound healing, and gives skin its elasticity. But the version found in naked mole rats is different. Their hyaluronan molecules are roughly five times longer than those in mice or humans, forming dense, viscous chains that saturate their tissues.
Gorbunova and Seluanov first identified this distinction in a 2013 Nature paper that traced the naked mole rat’s cancer resistance to these oversized hyaluronan chains. The molecule accumulates because of two factors: the animal’s version of the HAS2 gene produces longer chains, and the enzyme that normally breaks hyaluronan down (hyaluronidase) is less active. When the researchers removed the high-molecular-mass hyaluronan from naked mole rat cells, either by silencing HAS2 or by ramping up the breakdown enzyme, the cells lost their resistance to cancer. The link was direct and reproducible.
A follow-up study in 2020 added an important detail: the protective effect depends on chain length. The researchers characterized what they called “very-high-molecular-mass” hyaluronan, or vHMM-HA, and showed that longer chains offered greater protection against stress-induced cell damage. Shorter fragments of the same molecule did not provide the same benefit. This length dependence helps explain why simply having hyaluronan, as all mammals do, is not enough. What matters is having the right kind.
What happened when mice got the gene
The central experiment in the 2023 study involved engineering transgenic mice to carry nmrHas2, the naked mole rat’s version of hyaluronan synthase 2. These mice expressed the gene from early development onward, producing elevated levels of high-molecular-mass hyaluronan across multiple tissues, including skin, heart, and muscle.
The outcomes were measurable on several fronts. The transgenic mice showed a 4.4% increase in median lifespan compared to controls. They developed spontaneous tumors at significantly lower rates. And they aged with fewer visible complications: better maintenance of body weight in late life, reduced age-related inflammation in certain tissues, and fewer signs of organ degeneration under microscopic examination.
A 4.4% lifespan gain from a single gene may sound modest, but in aging biology, where interventions often target dozens of pathways at once, a measurable extension from one genetic change is notable. More importantly, the mice did not just survive slightly longer. They appeared to stay healthier while doing it, which researchers describe as an improvement in “healthspan” rather than just lifespan.
Even so, the engineered mice did not fully replicate naked mole rat biology. Their hyaluronan levels rose substantially but still fell short of the concentrations found in actual naked mole rat tissues. The partial shift was enough to produce clear benefits, but it also suggests that the full protective potential of the molecule was not reached in this experiment.
What the research does not yet show
The gap between a transgenic mouse and a human therapy is enormous, and several critical questions remain open.
No research group has tested nmrHas2 overexpression in larger mammals such as rats, dogs, or primates. No published data exist on long-term side effects beyond the study’s observation window. And no one has demonstrated whether initiating hyaluronan overproduction in adulthood, rather than from the embryonic stage, would produce comparable results. In any realistic clinical scenario, a therapy would be started later in life, not before birth.
The molecular mechanism behind hyaluronan’s protective effects also remains only partially mapped. The polymer interacts with multiple cell-surface receptors, influences the structure of the extracellular matrix, and can modulate immune responses. Which of these roles matters most for cancer resistance and longevity is still an open question. The 2020 study established that chain length is critical, but the downstream signaling pathways have not been fully characterized.
It is also unclear how broadly the benefits extend across different diseases. The mouse data show reduced spontaneous tumors and some improvements in organ integrity, but the study did not test whether nmrHas2 expression alters the course of neurodegeneration, metabolic disease, or cardiovascular decline. Without disease-specific models and longer follow-up, the full scope of the molecule’s impact on aging remains uncertain.
One question readers may reasonably ask: could hyaluronan supplements or injections, already widely sold for joint health and skin care, replicate any of these effects? Almost certainly not. Commercial hyaluronan products contain molecules far shorter than the vHMM-HA produced by the naked mole rat gene, and the 2020 research showed that shorter chains do not confer the same protection. The benefit appears to require the specific, unusually long polymer that nmrHas2 generates inside cells, not hyaluronan applied externally or swallowed as a supplement.
Hyaluronan is one piece of a larger puzzle
Naked mole rat longevity almost certainly involves more than a single molecule. Researchers studying the species have identified contributions from enhanced genome stability, efficient suppression of transposable genetic elements, superior protein quality control, and unusual metabolic adaptations to low-oxygen environments. Hyaluronan may work in concert with these other mechanisms, or it may depend on them to achieve its full protective effect.
Treating high-molecular-mass hyaluronan as the sole explanation for a multi-decade lifespan would overstate the evidence. What the Rochester team demonstrated is more specific and, in some ways, more useful: that isolating one component of the naked mole rat’s biology and transferring it to another species can produce real, measurable health benefits. That is a proof of concept, not a cure for aging.
No clinical trials, no approved therapies, and a long road ahead
As of June 2026, there are no approved drugs or gene therapies based on nmrHas2. No registered clinical trials are testing high-molecular-mass hyaluronan as an anti-aging intervention in humans. No regulatory pathway has been established for this approach. The fundamental question of whether increasing hyaluronan length or abundance in human tissues would be safe over decades has not been addressed in any published study.
What exists is a clean, peer-reviewed result: a single gene from the world’s longest-lived rodent, placed into mice, extended their lives and reduced their cancer rates. That finding has held up to scrutiny and remains one of the more striking results in recent aging research. But the distance between a transgenic mouse born with an extra gene and a treatment that could benefit a 60-year-old human patient is vast, and no shortcut through that distance has appeared yet.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
